Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revisionBoth sides next revision | ||
resources:fluoroquinolones [2018/12/14 01:05] bpaddock Add European Medicines Agency info. | resources:fluoroquinolones [2019/12/25 00:40] bpaddock Added ruptures or tears in the aorta blood vessel FDA warning. | ||
---|---|---|---|
Line 57: | Line 57: | ||
---- | ---- | ||
+ | <WRAP warning> | ||
+ | ====== FDA warns about increased risk of ruptures or tears in the aorta blood vessel ====== | ||
+ | FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients | ||
+ | |||
+ | < | ||
+ | Safety Announcement | ||
+ | [12-20-2018] A U.S. Food and Drug Administration (FDA) review found that fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the main artery of the body, called the aorta. | ||
+ | |||
+ | Fluoroquinolones should not be used in patients at increased risk unless there are no other treatment options available. | ||
+ | |||
+ | Fluoroquinolone antibiotics are approved to treat certain bacterial infections and have been used for more than 30 years. | ||
+ | |||
+ | Health care professionals should avoid prescribing fluoroquinolone antibiotics to patients who have an aortic aneurysm or are at risk for an aortic aneurysm, such as patients with peripheral atherosclerotic vascular diseases, hypertension, | ||
+ | |||
+ | Patients should seek medical attention immediately by going to an emergency room or calling 911 if you experience sudden, severe, and constant pain in the stomach, chest or back. Be aware that symptoms of an aortic aneurysm often do not show up until the aneurysm becomes large or bursts, so report any unusual side effects from taking fluoroquinolones to your health care professional immediately. | ||
+ | |||
+ | We reviewed cases reported to FDA* and four published observational studies1, | ||
+ | |||
+ | We communicated safety information associated with fluoroquinolones in July 2018 (significant decreases in blood sugar and certain mental health side effects), July 2016 (disabling side effects of the tendons, muscles, joints, nerves, and central nervous system), May 2016 (restricting use for certain uncomplicated infections), | ||
+ | |||
+ | To help FDA track safety issues with medicines, we urge patients and health care professionals to report side effects involving fluoroquinolones or other medicines to the FDA MedWatch program, using the information in the “Contact FDA” box at the bottom of the page. | ||
+ | |||
+ | *The cases were reported to the FDA Adverse Event Reporting System (FAERS). [Which gets only 1% of actual reports!] | ||
+ | |||
+ | </ | ||
+ | |||
+ | ### | ||
+ | Release: | ||
+ | ### ---- https:// | ||
+ | </ | ||
<WRAP warning> | <WRAP warning> | ||
Line 139: | Line 169: | ||
because these patients are at a higher risk of tendon injury. //Since the use of a corticosteroid with a | because these patients are at a higher risk of tendon injury. //Since the use of a corticosteroid with a | ||
fluoroquinolone also increases this risk, combined use of these medicines should be avoided// | fluoroquinolone also increases this risk, combined use of these medicines should be avoided// | ||
- | // | + | // |
October 5th 2018: | October 5th 2018: | ||
Line 149: | Line 179: | ||
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of fluoroquinolone and quinolone antibiotics (used by mouth, injection or inhalation) following a review of disabling and potentially long-lasting side effects reported with these medicines. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. | The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of fluoroquinolone and quinolone antibiotics (used by mouth, injection or inhalation) following a review of disabling and potentially long-lasting side effects reported with these medicines. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. | ||
- | Very rarely [**//__THIS IS NOT TRUE, NOT RARE AT ALL__//], patients treated with fluoroquinolone or quinolone antibiotics have suffered long-lasting and disabling side effects, mainly involving muscles, tendons and bones and the nervous system. | + | Very rarely [**//__THIS IS NOT TRUE, NOT RARE AT ALL__//**], patients treated with fluoroquinolone or quinolone antibiotics have suffered long-lasting and disabling side effects, mainly involving muscles, tendons and bones and the nervous system. |
- | Following its evaluation of these side effects, the PRAC has recommended that some medicines, including all those that contain a quinolone antibiotic, should be removed from the market. This is because they are authorised only for infections that should no longer be treated with this class of antibiotics. | + | < |
The PRAC recommended that the remaining fluoroquinolone antibiotics should: | The PRAC recommended that the remaining fluoroquinolone antibiotics should: | ||
Line 162: | Line 192: | ||
* be used with caution especially for the elderly [They should not be used in the elderly at all], patients with kidney problems, patients who have had an organ transplantation or those who are being treated with a systemic corticosteroid. These patients are at higher risk of tendon injury caused by fluoroquinolone and quinolone antibiotics. | * be used with caution especially for the elderly [They should not be used in the elderly at all], patients with kidney problems, patients who have had an organ transplantation or those who are being treated with a systemic corticosteroid. These patients are at higher risk of tendon injury caused by fluoroquinolone and quinolone antibiotics. | ||
- | The PRAC also recommended that healthcare professionals should advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or bones (such as inflamed or torn tendon, muscle pain or weakness, and joint pain or swelling) or the nervous system (such as feeling pins and needles, tiredness, depression, confusion, suicidal thoughts, sleep disorders, vision and hearing problems, and altered taste and smell).</ | + | The PRAC also recommended that healthcare professionals should advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or bones (such as inflamed or torn tendon, muscle pain or weakness, and joint pain or swelling) or the nervous system (such as feeling pins and needles, tiredness, depression, confusion, suicidal thoughts, sleep disorders, vision and hearing problems, and altered taste and smell).</ |
June 13th 2018: | June 13th 2018: |